Form 4 for INSM INSMED Inc
Accepted 2021-11-03 00:00:00 ET · period of report 2021-11-01 · accession 0001140361-21-036424 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2021-11-03 | 2021-11-01 | INSM | Schaeffer Orlov S Nicole | Chief People Strategy Off | S - Sale+OE | $30.28 | -61.0K | 51.9K | -54% | -$1.85M |
| D | 2021-11-03 | 2021-11-01 | INSM | Schaeffer Orlov S Nicole | Chief People Strategy Off | M - OptEx | $12.44 | +61.0K | 112.5K | +118% | +$758.8K |
| DM | 2021-11-03 | 2021-11-01 | INSM | Schaeffer Orlov S Nicole | Chief People Strategy Off | M - OptEx | $0.00 | -61.0K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2021-11-01 | S | D | 340 | $31.08 | 51,514 | D | — | — | (F4) This is the weighted average sales price representing 340 shares sold at prices ranging from $31.00 to $31.14 per share. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. |
| 2 | Common | Common Stock | 2021-11-01 | S | D | 60,660 | $30.28 | 51,854 | D | — | — | (F3) This is the weighted average sales price representing 60,660 shares sold at prices ranging from $30.00 to $30.99 per share. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. |
| 3 | Common | Common Stock | 2021-11-01 | M | A | 61,000 | $12.44 | 112,514 | D | — | — | (F2) Includes 722 shares acquired through the Company's 2018 Employee Stock Purchase Plan. |
| 4 | Derivative | Stock Option (right to buy) | 2021-11-01 | M | D | 36,000 | $0.00 | 25,000 | D | $12.44 · — to 2023-05-23 | 36,000 Common Stock | (F5) The options became exercisable based on the following vesting schedule: twenty five percent (25%) vested on the first anniversary of the grant date and an additional twelve and one half percent (12.5%) vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. |
| 5 | Derivative | Stock Option (right to buy) | 2021-11-01 | M | D | 25,000 | $0.00 | 0 | D | $12.44 · — to 2023-05-23 | 25,000 Common Stock | (F6) These options vested and became exercisable with respect to 12,500 shares upon receipt of the first written acceptance of an NDA or MAA filing from an applicable regulatory authority (FDA or EMA); and with respect to the remaining 12,500 shares upon receipt of the first written approval of an NDA or MAA filing from an applicable regulatory authority (FDA or EMA). |